Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans

A cross-ethnic comparative study

Huai Rong Luo, Russell E. Poland, Keh Ming Lin, Yu-Jui Yvonne Wan

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Objectives: Our objectives were to investigate cytochrome P450 (CYP) 2C19 polymorphism in Mexican Americans and compare the findings with those in 4 other ethnic groups. Methods: The CYP2C19 genotype (n = 346) and S-mephenytoin hydroxylation phenotype (n = 220) were studied in a Mexican American population from Los Angeles County. Another 4 ethnic groups, African Americans (n = 236), whites (n = 273), East Asians (n = 161), and Southeast Asians (n = 80), were also recruited from Los Angeles County and genotyped and phenotyped for CYP2C19. Results: The frequencies of CYP2C19*2 and *3 were 9.7% and 0.1%, respectively, in Mexican Americans, which were lower than those of the other 4 ethnic groups, ranging from 12.7% to 31.2% and 0.8% to 9.6%, respectively (P ≤ .035). Seven Mexican American subjects were phenotyped as poor metabolizers. Thus the frequency of poor metabolizers in the Mexican American subjects was 3.2% (95% confidence interval, 0%-11.9%), which is similar to that of African Americans (5.4%) and whites (5.0%) and lower than that of East Asians (16.7%; P < .001) and Southeast Asians (23.9%; P < .001). Of the 7 poor metabolizers who were also genotyped, 2 were homozygous for the CYP2C19*2 alleles. CYP2C19*4, *5, *6, *7, and *8 were studied and did not account for the unexplained finding. The number of functional alleles among the extensive metabolizers correlated with the phenotype, suggesting a gene-dosage effect in Mexican Americans. Conclusions: This is the first study to investigate CYP2C19 polymorphism in Mexican Americans. The frequencies of the CYP2C19*2 and *3 alleles in Mexican Americans were found to be significantly lower than in other ethnic groups. This genotypic pattern might be responsible for the lower rate of poor metabolizers in Mexican Americans compared with other ethnic groups.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume80
Issue number1
DOIs
StatePublished - Jul 2006
Externally publishedYes

Fingerprint

Genetic Polymorphisms
Cytochrome P-450 Enzyme System
Ethnic Groups
Los Angeles
Alleles
African Americans
Mephenytoin
Phenotype
Gene Dosage
Hydroxylation
Cytochrome P-450 CYP2C19
Genotype
Confidence Intervals

ASJC Scopus subject areas

  • Pharmacology

Cite this

Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans : A cross-ethnic comparative study. / Luo, Huai Rong; Poland, Russell E.; Lin, Keh Ming; Wan, Yu-Jui Yvonne.

In: Clinical Pharmacology and Therapeutics, Vol. 80, No. 1, 07.2006, p. 33-40.

Research output: Contribution to journalArticle

@article{7a5dd76250bd4847890cc001e9f8214d,
title = "Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: A cross-ethnic comparative study",
abstract = "Objectives: Our objectives were to investigate cytochrome P450 (CYP) 2C19 polymorphism in Mexican Americans and compare the findings with those in 4 other ethnic groups. Methods: The CYP2C19 genotype (n = 346) and S-mephenytoin hydroxylation phenotype (n = 220) were studied in a Mexican American population from Los Angeles County. Another 4 ethnic groups, African Americans (n = 236), whites (n = 273), East Asians (n = 161), and Southeast Asians (n = 80), were also recruited from Los Angeles County and genotyped and phenotyped for CYP2C19. Results: The frequencies of CYP2C19*2 and *3 were 9.7{\%} and 0.1{\%}, respectively, in Mexican Americans, which were lower than those of the other 4 ethnic groups, ranging from 12.7{\%} to 31.2{\%} and 0.8{\%} to 9.6{\%}, respectively (P ≤ .035). Seven Mexican American subjects were phenotyped as poor metabolizers. Thus the frequency of poor metabolizers in the Mexican American subjects was 3.2{\%} (95{\%} confidence interval, 0{\%}-11.9{\%}), which is similar to that of African Americans (5.4{\%}) and whites (5.0{\%}) and lower than that of East Asians (16.7{\%}; P < .001) and Southeast Asians (23.9{\%}; P < .001). Of the 7 poor metabolizers who were also genotyped, 2 were homozygous for the CYP2C19*2 alleles. CYP2C19*4, *5, *6, *7, and *8 were studied and did not account for the unexplained finding. The number of functional alleles among the extensive metabolizers correlated with the phenotype, suggesting a gene-dosage effect in Mexican Americans. Conclusions: This is the first study to investigate CYP2C19 polymorphism in Mexican Americans. The frequencies of the CYP2C19*2 and *3 alleles in Mexican Americans were found to be significantly lower than in other ethnic groups. This genotypic pattern might be responsible for the lower rate of poor metabolizers in Mexican Americans compared with other ethnic groups.",
author = "Luo, {Huai Rong} and Poland, {Russell E.} and Lin, {Keh Ming} and Wan, {Yu-Jui Yvonne}",
year = "2006",
month = "7",
doi = "10.1016/j.clpt.2006.03.003",
language = "English (US)",
volume = "80",
pages = "33--40",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans

T2 - A cross-ethnic comparative study

AU - Luo, Huai Rong

AU - Poland, Russell E.

AU - Lin, Keh Ming

AU - Wan, Yu-Jui Yvonne

PY - 2006/7

Y1 - 2006/7

N2 - Objectives: Our objectives were to investigate cytochrome P450 (CYP) 2C19 polymorphism in Mexican Americans and compare the findings with those in 4 other ethnic groups. Methods: The CYP2C19 genotype (n = 346) and S-mephenytoin hydroxylation phenotype (n = 220) were studied in a Mexican American population from Los Angeles County. Another 4 ethnic groups, African Americans (n = 236), whites (n = 273), East Asians (n = 161), and Southeast Asians (n = 80), were also recruited from Los Angeles County and genotyped and phenotyped for CYP2C19. Results: The frequencies of CYP2C19*2 and *3 were 9.7% and 0.1%, respectively, in Mexican Americans, which were lower than those of the other 4 ethnic groups, ranging from 12.7% to 31.2% and 0.8% to 9.6%, respectively (P ≤ .035). Seven Mexican American subjects were phenotyped as poor metabolizers. Thus the frequency of poor metabolizers in the Mexican American subjects was 3.2% (95% confidence interval, 0%-11.9%), which is similar to that of African Americans (5.4%) and whites (5.0%) and lower than that of East Asians (16.7%; P < .001) and Southeast Asians (23.9%; P < .001). Of the 7 poor metabolizers who were also genotyped, 2 were homozygous for the CYP2C19*2 alleles. CYP2C19*4, *5, *6, *7, and *8 were studied and did not account for the unexplained finding. The number of functional alleles among the extensive metabolizers correlated with the phenotype, suggesting a gene-dosage effect in Mexican Americans. Conclusions: This is the first study to investigate CYP2C19 polymorphism in Mexican Americans. The frequencies of the CYP2C19*2 and *3 alleles in Mexican Americans were found to be significantly lower than in other ethnic groups. This genotypic pattern might be responsible for the lower rate of poor metabolizers in Mexican Americans compared with other ethnic groups.

AB - Objectives: Our objectives were to investigate cytochrome P450 (CYP) 2C19 polymorphism in Mexican Americans and compare the findings with those in 4 other ethnic groups. Methods: The CYP2C19 genotype (n = 346) and S-mephenytoin hydroxylation phenotype (n = 220) were studied in a Mexican American population from Los Angeles County. Another 4 ethnic groups, African Americans (n = 236), whites (n = 273), East Asians (n = 161), and Southeast Asians (n = 80), were also recruited from Los Angeles County and genotyped and phenotyped for CYP2C19. Results: The frequencies of CYP2C19*2 and *3 were 9.7% and 0.1%, respectively, in Mexican Americans, which were lower than those of the other 4 ethnic groups, ranging from 12.7% to 31.2% and 0.8% to 9.6%, respectively (P ≤ .035). Seven Mexican American subjects were phenotyped as poor metabolizers. Thus the frequency of poor metabolizers in the Mexican American subjects was 3.2% (95% confidence interval, 0%-11.9%), which is similar to that of African Americans (5.4%) and whites (5.0%) and lower than that of East Asians (16.7%; P < .001) and Southeast Asians (23.9%; P < .001). Of the 7 poor metabolizers who were also genotyped, 2 were homozygous for the CYP2C19*2 alleles. CYP2C19*4, *5, *6, *7, and *8 were studied and did not account for the unexplained finding. The number of functional alleles among the extensive metabolizers correlated with the phenotype, suggesting a gene-dosage effect in Mexican Americans. Conclusions: This is the first study to investigate CYP2C19 polymorphism in Mexican Americans. The frequencies of the CYP2C19*2 and *3 alleles in Mexican Americans were found to be significantly lower than in other ethnic groups. This genotypic pattern might be responsible for the lower rate of poor metabolizers in Mexican Americans compared with other ethnic groups.

UR - http://www.scopus.com/inward/record.url?scp=33745418092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745418092&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2006.03.003

DO - 10.1016/j.clpt.2006.03.003

M3 - Article

VL - 80

SP - 33

EP - 40

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -